<DOC>
	<DOCNO>NCT01285479</DOCNO>
	<brief_summary>The purpose Multi-National Gilenya Pregnancy Exposure Registry Multiple Sclerosis ( MS ) continuously monitor , evaluate , assess major minor teratogenic effect offspring woman expose Gilenya ( 8 week last menstrual period ) pregnancy routine clinical practice . The overall aim collect evaluate data maternal , fetal , infant outcome compare reference population .</brief_summary>
	<brief_title>Pregnancy Registry Trial</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Pregnancy report confirm suspected maternal exposure Gilenya time pregnancy shortly pregnancy ( 8 week LMP ) . Informed consent There specific exclusion criterion registry . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fingolimod</keyword>
	<keyword>FTY720</keyword>
	<keyword>Gilenya</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Safety</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy outcome</keyword>
</DOC>